Danaher (NYSE:DHR) Price Target Raised to $270.00

Danaher (NYSE:DHR) had its target price increased by TD Cowen from $255.00 to $270.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the conglomerate’s stock.

Several other equities research analysts have also recently issued reports on the stock. Royal Bank Of Canada boosted their price objective on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Sunday, October 18th. Wells Fargo & Company reduced their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Guggenheim lifted their price target on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $242.91.

Danaher Trading Up 0.3%

NYSE DHR opened at $230.36 on Thursday. The company’s 50-day moving average price is $216.32 and its 200-day moving average price is $197.35. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 0.45. The stock has a market cap of $162.07 billion, a PE ratio of 37.70, a PEG ratio of 2.88 and a beta of 0.76. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, topping the consensus estimate of $1.92 by $0.19. The company had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The firm’s revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.89 EPS. Equities research analysts forecast that Danaher will post 8.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is currently 26.19%.

Institutional Trading of Danaher

Hedge funds have recently modified their holdings of the company. Gunderson Capital Management LLC bought a new position in shares of Danaher during the 3rd quarter worth approximately $765,000. EP Wealth Advisors LLC purchased a new stake in Danaher during the second quarter valued at approximately $3,807,000. Frank Rimerman Advisors LLC boosted its stake in Danaher by 181.9% in the third quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock valued at $9,051,000 after acquiring an additional 26,363 shares in the last quarter. Birch Hill Investment Advisors LLC boosted its stake in Danaher by 9.6% in the third quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock valued at $8,984,000 after acquiring an additional 3,553 shares in the last quarter. Finally, Forbes J M & Co. LLP boosted its stake in Danaher by 141.6% in the third quarter. Forbes J M & Co. LLP now owns 4,276 shares of the conglomerate’s stock valued at $947,000 after acquiring an additional 2,506 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.